L M Pop1, I Lingvay1,2, Q Yuan3, X Li2, B Adams-Huet2,4,5, N M Maalouf6,7. 1. Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA. 2. Department of Clinical Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA. 3. Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA. 4. Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8885, USA. 5. Department of Internal Medicine, Division of Mineral Metabolism, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8885, USA. 6. Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8885, USA. Naim.Maalouf@UTSouthwestern.edu. 7. Department of Internal Medicine, Division of Mineral Metabolism, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8885, USA. Naim.Maalouf@UTSouthwestern.edu.
Abstract
Pioglitazone use is associated with an increased risk of fractures. In this randomized, placebo-controlled study, pioglitazone use for 12 months was associated with a significant increase in bone marrow fat content at the femoral neck, accompanied by a significant decrease in total hip bone mineral density. The change in bone marrow fat with pioglitazone use was predominantly observed in female vs. male participants. INTRODUCTION: Use of the insulin sensitizer pioglitazone is associated with greater fracture incidence, although the underlying mechanisms are incompletely understood. This study aimed to assess the effect of pioglitazone treatment on femoral neck bone marrow (BM) fat content and on bone mineral density (BMD), and to establish if any correlation exists between the changes in these parameters. METHODS: In this double-blind placebo-controlled clinical trial, 42 obese volunteers with metabolic syndrome were randomized to pioglitazone (45 mg/day) or matching placebo for 1 year. The following measurements were conducted at baseline and during the treatment: liver, pancreas, and femoral neck BM fat content (by magnetic resonance spectroscopy), BMD by DXA, abdominal subcutaneous and visceral fat, and beta-cell function and insulin sensitivity. RESULTS: Results were available for 37 subjects who completed the baseline and 1-year evaluations. At 12 months, BM fat increased with pioglitazone (absolute change, +4.1%, p = 0.03), whereas BM fat content in the placebo group decreased non-significantly (-3.1%, p = 0.08) (p = 0.007 for the pioglitazone-placebo response difference). Total hip BMD declined in the pioglitazone group (-1.4%) and increased by 0.8% in the placebo group (p = 0.03 between groups). The change in total hip BMD was inversely and significantly correlated with the change in BM fat content (Spearman rho = -0.56, p = 0.01) in the pioglitazone group, but not within the placebo group (rho = -0.29, p = 0.24). Changes in BM fat with pioglitazone were predominantly observed in female vs. male subjects. CONCLUSIONS:Pioglitazone use for 12 months compared with placebo is associated with significant increase in BM fat content at the femoral neck, accompanied by a small but significant decrease in total hip BMD.
RCT Entities:
Pioglitazone use is associated with an increased risk of fractures. In this randomized, placebo-controlled study, pioglitazone use for 12 months was associated with a significant increase in bone marrow fat content at the femoral neck, accompanied by a significant decrease in total hip bone mineral density. The change in bone marrow fat with pioglitazone use was predominantly observed in female vs. male participants. INTRODUCTION: Use of the insulin sensitizer pioglitazone is associated with greater fracture incidence, although the underlying mechanisms are incompletely understood. This study aimed to assess the effect of pioglitazone treatment on femoral neck bone marrow (BM) fat content and on bone mineral density (BMD), and to establish if any correlation exists between the changes in these parameters. METHODS: In this double-blind placebo-controlled clinical trial, 42 obese volunteers with metabolic syndrome were randomized to pioglitazone (45 mg/day) or matching placebo for 1 year. The following measurements were conducted at baseline and during the treatment: liver, pancreas, and femoral neck BM fat content (by magnetic resonance spectroscopy), BMD by DXA, abdominal subcutaneous and visceral fat, and beta-cell function and insulin sensitivity. RESULTS: Results were available for 37 subjects who completed the baseline and 1-year evaluations. At 12 months, BM fat increased with pioglitazone (absolute change, +4.1%, p = 0.03), whereas BM fat content in the placebo group decreased non-significantly (-3.1%, p = 0.08) (p = 0.007 for the pioglitazone-placebo response difference). Total hip BMD declined in the pioglitazone group (-1.4%) and increased by 0.8% in the placebo group (p = 0.03 between groups). The change in total hip BMD was inversely and significantly correlated with the change in BM fat content (Spearman rho = -0.56, p = 0.01) in the pioglitazone group, but not within the placebo group (rho = -0.29, p = 0.24). Changes in BM fat with pioglitazone were predominantly observed in female vs. male subjects. CONCLUSIONS:Pioglitazone use for 12 months compared with placebo is associated with significant increase in BM fat content at the femoral neck, accompanied by a small but significant decrease in total hip BMD.
Entities:
Keywords:
Bone Marrow Fat; Bone Mineral Density; Fracture; Pioglitazone
Authors: Liv Thommesen; Astrid Kamilla Stunes; Marta Monjo; Kristin Grøsvik; Margareth V Tamburstuen; Eli Kjøbli; Ståle Petter Lyngstadaas; Janne E Reseland; Unni Syversen Journal: J Cell Biochem Date: 2006-10-15 Impact factor: 4.429
Authors: James F Griffith; David K W Yeung; Steven K K Chow; Jason Chi Shun Leung; Ping Chung Leung Journal: J Magn Reson Imaging Date: 2009-06 Impact factor: 4.813
Authors: S Benvenuti; I Cellai; P Luciani; C Deledda; R Saccardi; B Mazzanti; S Dal Pozzo; M Serio; A Peri Journal: J Endocrinol Invest Date: 2011-05-19 Impact factor: 4.256
Authors: Jasminder Sahi; Christopher B Black; Geraldine A Hamilton; Xianxian Zheng; Summer Jolley; Kelly A Rose; Darryl Gilbert; Edward L LeCluyse; Michael W Sinz Journal: Drug Metab Dispos Date: 2003-04 Impact factor: 3.922
Authors: Janina M Patsch; Xiaojuan Li; Thomas Baum; Samuel P Yap; Dimitrios C Karampinos; Ann V Schwartz; Thomas M Link Journal: J Bone Miner Res Date: 2013-08 Impact factor: 6.741
Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray Journal: Lancet Date: 2009-06-06 Impact factor: 79.321
Authors: Jong Suk Park; Min Ho Cho; Ji Sun Nam; Jeong Seon Yoo; Chul Woo Ahn; Bong Soo Cha; Kyung Rae Kim; Hyun Chul Lee Journal: Eur J Endocrinol Date: 2010-10-20 Impact factor: 6.664
Authors: Zachary L Sebo; Elizabeth Rendina-Ruedy; Gene P Ables; Dieter M Lindskog; Matthew S Rodeheffer; Pouneh K Fazeli; Mark C Horowitz Journal: Endocr Rev Date: 2019-10-01 Impact factor: 19.871
Authors: Naim M Maalouf; John R Poindexter; Beverley Adams-Huet; Orson W Moe; Khashayar Sakhaee Journal: Kidney Int Date: 2019-02-19 Impact factor: 10.612
Authors: Andrea B Kirk; Stephani Michelsen-Correa; Cliff Rosen; Clyde F Martin; Bruce Blumberg Journal: Endocrinology Date: 2021-12-01 Impact factor: 5.051
Authors: Gina N Woods; Susan K Ewing; Anne L Schafer; Vilmundur Gudnason; Sigurdur Sigurdsson; Thomas Lang; Trisha F Hue; Deborah M Kado; Eric Vittinghoff; Clifford Rosen; Xiaojuan Li; Ann V Schwartz Journal: J Bone Miner Res Date: 2022-01-31 Impact factor: 6.390
Authors: Quan M Nhu; Lance Hsieh; Lucas Dohil; Ranjan Dohil; Robert O Newbury; Richard Kurten; Fouad J Moawad; Seema S Aceves Journal: Clin Transl Gastroenterol Date: 2020-04 Impact factor: 4.396